Menu
← Oncology Approval Tracker
FDA DECISION ·
Camcevi
leuprolide mesylate · Foresee Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with advanced prostate cancer treated with a six-month subcutaneous leuprolide mesylate depot.
LAMPGEN ANALYSIS
Why it matters
The approval adds a long-interval depot presentation for androgen deprivation.
What research teams should watch
Verify the formulation and injection date and align subsequent administrations with testosterone follow-up.
PRIMARY RECORDS